Eplerenone
Eplerenone market is segmented by region (country), players, by Type and by Application. Players, ... Read More
Global and United States Adalimumab Market Report & Forecast 2024-2031
1 Study Coverage
1.1 Adalimumab Product Introduction
1.2 Global Adalimumab Outlook 2017 VS 2022 VS 2028
1.2.1 Global Adalimumab Sales in US$ Million for the Year 2017-2028
1.2.2 Global Adalimumab Sales in Volume for the Year 2017-2028
1.3 United States Adalimumab Outlook 2017 VS 2022 VS 2028
1.3.1 United States Adalimumab Sales in US$ Million for the Year 2017-2028
1.3.2 United States Adalimumab Sales in Volume for the Year 2017-2028
1.4 Adalimumab Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4.1 The Market Share of United States Adalimumab in Global, 2017 VS 2022 VS 2028
1.4.2 The Growth Rate of Adalimumab Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.5 Adalimumab Market Dynamics
1.5.1 Adalimumab Industry Trends
1.5.2 Adalimumab Market Drivers
1.5.3 Adalimumab Market Challenges
1.5.4 Adalimumab Market Restraints
1.6 Study Objectives
1.7 Years Considered
2 Market by Type
2.1 Adalimumab Market Segment by Type
2.1.1 Adalimumab
2.1.2 Adalimumab Biosimilar
2.2 Global Adalimumab Market Size by Type
2.2.1 Global Adalimumab Sales in Value, by Type (2017, 2022 & 2028)
2.2.2 Global Adalimumab Sales in Volume, by Type (2017, 2022 & 2028)
2.2.3 Global Adalimumab Average Selling Price (ASP) by Type (2017, 2022 & 2028)
2.3 United States Adalimumab Market Size by Type
2.3.1 United States Adalimumab Sales in Value, by Type (2017, 2022 & 2028)
2.3.2 United States Adalimumab Sales in Volume, by Type (2017, 2022 & 2028)
2.3.3 United States Adalimumab Average Selling Price (ASP) by Type (2017, 2022 & 2028)
3 Market by Application
3.1 Adalimumab Market Segment by Application
3.1.1 Adults
3.1.2 Children
3.2 Global Adalimumab Market Size by Application
3.2.1 Global Adalimumab Sales in Value, by Application (2017, 2022 & 2028)
3.2.2 Global Adalimumab Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 Global Adalimumab Average Selling Price (ASP) by Application (2017, 2022 & 2028)
3.3 United States Adalimumab Market Size by Application
3.3.1 United States Adalimumab Sales in Value, by Application (2017, 2022 & 2028)
3.3.2 United States Adalimumab Sales in Volume, by Application (2017, 2022 & 2028)
3.3.3 United States Adalimumab Average Selling Price (ASP) by Application (2017, 2022 & 2028)
4 Global Adalimumab Competitor Landscape by Company
4.1 Global Adalimumab Market Size by Company
4.1.1 Top Global Adalimumab Manufacturers Ranked by Revenue (2021)
4.1.2 Global Adalimumab Revenue by Manufacturer (2017-2022)
4.1.3 Global Adalimumab Sales by Manufacturer (2017-2022)
4.1.4 Global Adalimumab Price by Manufacturer (2017-2022)
4.2 Global Adalimumab Concentration Ratio (CR)
4.2.1 Adalimumab Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Adalimumab in 2021
4.2.3 Global Adalimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Adalimumab Manufacturing Base Distribution, Product Type
4.3.1 Global Adalimumab Manufacturers, Headquarters and Distribution of Producing Region
4.3.2 Manufacturers Adalimumab Product Type
4.3.3 Date of International Manufacturers Enter into Adalimumab Market
4.4 Manufacturers Mergers & Acquisitions, Expansion Plans
4.5 United States Adalimumab Market Size by Company
4.5.1 Top Adalimumab Players in United States, Ranked by Revenue (2021)
4.5.2 United States Adalimumab Revenue by Players (2020, 2021 & 2022)
4.5.3 United States Adalimumab Sales by Players (2020, 2021 & 2022)
5 Global Adalimumab Market Size by Region
5.1 Global Adalimumab Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Adalimumab Market Size in Volume by Region (2017-2028)
5.2.1 Global Adalimumab Sales in Volume by Region: 2017-2022
5.2.2 Global Adalimumab Sales in Volume Forecast by Region (2023-2028)
5.3 Global Adalimumab Market Size in Value by Region (2017-2028)
5.3.1 Global Adalimumab Sales in Value by Region: 2017-2022
5.3.2 Global Adalimumab Sales in Value by Region: 2023-2028
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Adalimumab Market Size YoY Growth 2017-2028
6.1.2 North America Adalimumab Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Adalimumab Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Adalimumab Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Adalimumab Market Size YoY Growth 2017-2028
6.3.2 Europe Adalimumab Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Adalimumab Market Size YoY Growth 2017-2028
6.4.2 Latin America Adalimumab Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Adalimumab Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Adalimumab Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 AbbVie
7.1.1 AbbVie Corporation Information
7.1.2 AbbVie Description and Business Overview
7.1.3 AbbVie Adalimumab Sales, Revenue and Gross Margin (2017-2022)
7.1.4 AbbVie Adalimumab Products Offered
7.1.5 AbbVie Recent Development
7.2 Amgen
7.2.1 Amgen Corporation Information
7.2.2 Amgen Description and Business Overview
7.2.3 Amgen Adalimumab Sales, Revenue and Gross Margin (2017-2022)
7.2.4 Amgen Adalimumab Products Offered
7.2.5 Amgen Recent Development
7.3 Sandoz
7.3.1 Sandoz Corporation Information
7.3.2 Sandoz Description and Business Overview
7.3.3 Sandoz Adalimumab Sales, Revenue and Gross Margin (2017-2022)
7.3.4 Sandoz Adalimumab Products Offered
7.3.5 Sandoz Recent Development
7.4 Boehringer Ingelheim
7.4.1 Boehringer Ingelheim Corporation Information
7.4.2 Boehringer Ingelheim Description and Business Overview
7.4.3 Boehringer Ingelheim Adalimumab Sales, Revenue and Gross Margin (2017-2022)
7.4.4 Boehringer Ingelheim Adalimumab Products Offered
7.4.5 Boehringer Ingelheim Recent Development
7.5 Mylan
7.5.1 Mylan Corporation Information
7.5.2 Mylan Description and Business Overview
7.5.3 Mylan Adalimumab Sales, Revenue and Gross Margin (2017-2022)
7.5.4 Mylan Adalimumab Products Offered
7.5.5 Mylan Recent Development
7.6 Biogen
7.6.1 Biogen Corporation Information
7.6.2 Biogen Description and Business Overview
7.6.3 Biogen Adalimumab Sales, Revenue and Gross Margin (2017-2022)
7.6.4 Biogen Adalimumab Products Offered
7.6.5 Biogen Recent Development
8 Industry Chain and Sales Channels Analysis
8.1 Adalimumab Industry Chain Analysis
8.2 Adalimumab Key Raw Materials
8.2.1 Key Raw Materials
8.2.2 Adalimumab Distributors
8.3 Adalimumab Production Mode & Process
8.4 Adalimumab Sales and Marketing
8.4.1 Adalimumab Sales Channels
8.4.2 Adalimumab Distributors
8.5 Adalimumab Customers
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Adalimumab CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
Table 2. Adalimumab Market Trends
Table 3. Adalimumab Market Drivers
Table 4. Adalimumab Market Challenges
Table 5. Adalimumab Market Restraints
Table 6. Global Adalimumab Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 7. United States Adalimumab Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
Table 8. Global Adalimumab Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 9. United States Adalimumab Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
Table 10. Top Adalimumab Manufacturers in Global Market, Ranking by Revenue (2021)
Table 11. Global Adalimumab Revenue by Manufacturer, (US$ Million), 2017-2022
Table 12. Global Adalimumab Revenue Share by Manufacturer, 2017-2022
Table 13. Global Adalimumab Sales by Manufacturer, (K Units), 2017-2022
Table 14. Global Adalimumab Sales Share by Manufacturer, 2017-2022
Table 15. Global Adalimumab Price by Manufacturer (2017-2022) & (USD/Unit)
Table 16. Global Adalimumab Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Adalimumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab as of 2021)
Table 18. Top Players of Adalimumab in Global Market, Headquarters and Distribution of Producing Region
Table 19. Manufacturers Adalimumab Product Type
Table 20. Date of International Manufacturers Enter into Adalimumab Market
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Top Adalimumab Players in United States Market, Ranking by Revenue (2021)
Table 23. United States Adalimumab Revenue by Players, (US$ Million), 2020, 2021 & 2022
Table 24. United States Adalimumab Revenue Share by Players, 2020, 2021 & 2022
Table 25. United States Adalimumab Sales by Players, (K Units), 2020, 2021 & 2022
Table 26. United States Adalimumab Sales Share by Players, 2020, 2021 & 2022
Table 27. Global Adalimumab Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
Table 28. Global Adalimumab Sales in Volume by Region (2017-2022) & (K Units)
Table 29. Global Adalimumab Sales in Volume Forecast by Region (2023-2028) & (K Units)
Table 30. Global Adalimumab Sales in Value by Region (2017-2022) & (US$ Million)
Table 31. Global Adalimumab Sales in Value Forecast by Region (2023-2028) & (US$ Million)
Table 32. North America Adalimumab Sales in Volume by Country (2017-2028) & (K Units)
Table 33. North America Adalimumab Sales in Value by Country (2017-2028) & (US$ Million)
Table 34. Asia Pacific Adalimumab Sales in Volume by Region (2017-2028) & (K Units)
Table 35. Asia Pacific Adalimumab Sales in Value by Region (2017-2028) & (US$ Million)
Table 36. Europe Adalimumab Sales in Volume by Country (2017-2028) & (K Units)
Table 37. Europe Adalimumab Sales in Value by Country (2017-2028) & (US$ Million)
Table 38. Latin America Adalimumab Sales in Volume by Country (2017-2028) & (K Units)
Table 39. Latin Americaa Adalimumab Sales in Value by Country (2017-2028) & (US$ Million)
Table 40. Middle East and Africa Adalimumab Sales in Volume by Country (2017-2028) & (K Units)
Table 41. Middle East and Africa Adalimumab Sales in Value by Country (2017-2028) & (US$ Million)
Table 42. AbbVie Corporation Information
Table 43. AbbVie Description and Business Overview
Table 44. AbbVie Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 45. AbbVie Adalimumab Product
Table 46. AbbVie Recent Development
Table 47. Amgen Corporation Information
Table 48. Amgen Description and Business Overview
Table 49. Amgen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 50. Amgen Product
Table 51. Amgen Recent Development
Table 52. Sandoz Corporation Information
Table 53. Sandoz Description and Business Overview
Table 54. Sandoz Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 55. Sandoz Product
Table 56. Sandoz Recent Development
Table 57. Boehringer Ingelheim Corporation Information
Table 58. Boehringer Ingelheim Description and Business Overview
Table 59. Boehringer Ingelheim Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 60. Boehringer Ingelheim Product
Table 61. Boehringer Ingelheim Recent Development
Table 62. Mylan Corporation Information
Table 63. Mylan Description and Business Overview
Table 64. Mylan Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 65. Mylan Product
Table 66. Mylan Recent Development
Table 67. Biogen Corporation Information
Table 68. Biogen Description and Business Overview
Table 69. Biogen Adalimumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 70. Biogen Product
Table 71. Biogen Recent Development
Table 72. Key Raw Materials Lists
Table 73. Raw Materials Key Suppliers Lists
Table 74. Adalimumab Customers List
Table 75. Adalimumab Distributors List
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. Adalimumab Product Picture
Figure 2. Global Adalimumab Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 3. Global Adalimumab Market Size 2017-2028 (US$ Million)
Figure 4. Global Adalimumab Sales 2017-2028 (K Units)
Figure 5. United States Adalimumab Revenue, (US$ Million), 2017 VS 2022 VS 2028
Figure 6. United States Adalimumab Market Size 2017-2028 (US$ Million)
Figure 7. United States Adalimumab Sales 2017-2028 (K Units)
Figure 8. United States Adalimumab Market Share in Global, in Value (US$ Million) 2017-2028
Figure 9. United States Adalimumab Market Share in Global, in Volume (K Units) 2017-2028
Figure 10. Adalimumab Report Years Considered
Figure 11. Product Picture of Adalimumab
Figure 12. Product Picture of Adalimumab Biosimilar
Figure 13. Global Adalimumab Market Share by Type in 2022 & 2028
Figure 14. Global Adalimumab Sales in Value by Type (2017-2028) & (US$ Million)
Figure 15. Global Adalimumab Sales Market Share in Value by Type (2017-2028)
Figure 16. Global Adalimumab Sales by Type (2017-2028) & (K Units)
Figure 17. Global Adalimumab Sales Market Share in Volume by Type (2017-2028)
Figure 18. Global Adalimumab Price by Type (2017-2028) & (USD/Unit)
Figure 19. United States Adalimumab Market Share by Type in 2022 & 2028
Figure 20. United States Adalimumab Sales in Value by Type (2017-2028) & (US$ Million)
Figure 21. United States Adalimumab Sales Market Share in Value by Type (2017-2028)
Figure 22. United States Adalimumab Sales by Type (2017-2028) & (K Units)
Figure 23. United States Adalimumab Sales Market Share in Volume by Type (2017-2028)
Figure 24. United States Adalimumab Price by Type (2017-2028) & (USD/Unit)
Figure 25. Product Picture of Adults
Figure 26. Product Picture of Children
Figure 27. Global Adalimumab Market Share by Application in 2022 & 2028
Figure 28. Global Adalimumab Sales in Value by Application (2017-2028) & (US$ Million)
Figure 29. Global Adalimumab Sales Market Share in Value by Application (2017-2028)
Figure 30. Global Adalimumab Sales by Application (2017-2028) & (K Units)
Figure 31. Global Adalimumab Sales Market Share in Volume by Application (2017-2028)
Figure 32. Global Adalimumab Price by Application (2017-2028) & (USD/Unit)
Figure 33. United States Adalimumab Market Share by Application in 2022 & 2028
Figure 34. United States Adalimumab Sales in Value by Application (2017-2028) & (US$ Million)
Figure 35. United States Adalimumab Sales Market Share in Value by Application (2017-2028)
Figure 36. United States Adalimumab Sales by Application (2017-2028) & (K Units)
Figure 37. United States Adalimumab Sales Market Share in Volume by Application (2017-2028)
Figure 38. United States Adalimumab Price by Application (2017-2028) & (USD/Unit)
Figure 39. North America Adalimumab Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 40. North America Adalimumab Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 41. U.S. Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 42. Canada Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 43. Europe Adalimumab Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 44. Europe Adalimumab Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 45. Germany Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 46. France Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 47. U.K. Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 48. Italy Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 49. Russia Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 50. Asia-Pacific Adalimumab Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 51. Asia-Pacific Adalimumab Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 52. China Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 53. Japan Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 54. South Korea Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 55. India Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 56. Australia Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 57. Taiwan Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 58. Indonesia Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 59. Thailand Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 60. Malaysia Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 61. Philippines Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 62. Latin America Adalimumab Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 63. Latin America Adalimumab Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 64. Mexico Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 65. Brazil Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 66. Argentina Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 67. Middle East & Africa Adalimumab Sales in Volume Growth Rate 2017-2028 (K Units)
Figure 68. Middle East & Africa Adalimumab Sales in Value Growth Rate 2017-2028 (US$ Million)
Figure 69. Turkey Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 70. Saudi Arabia Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 71. U.A.E Adalimumab Sales in Value Growth Rate (2017-2028) & (US$ Million)
Figure 72. Adalimumab Value Chain
Figure 73. Adalimumab Production Process
Figure 74. Channels of Distribution
Figure 75. Distributors Profiles
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AbbVie Amgen Sandoz Boehringer Ingelheim Mylan Biogen